Aarti Drugs Limited (AARTIDRUGS.NS)
INR 354.05
(-2.56%)
INR 354.05
(-2.56%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 4.85 Billion INR | -5.89% |
| 2022 | 5.16 Billion INR | -1.84% |
| 2021 | 5.25 Billion INR | 26.73% |
| 2020 | 4.15 Billion INR | 27.53% |
| 2019 | 3.25 Billion INR | 31.95% |
| 2018 | 2.46 Billion INR | -11.36% |
| 2017 | 2.78 Billion INR | 32.71% |
| 2016 | 2.09 Billion INR | 17.54% |
| 2015 | 1.78 Billion INR | 8.62% |
| 2014 | 1.64 Billion INR | 29.57% |
| 2013 | 1.26 Billion INR | -10.07% |
| 2012 | 1.4 Billion INR | 43.93% |
| 2011 | 979.07 Million INR | 6.61% |
| 2010 | 918.33 Million INR | 42.58% |
| 2009 | 644.09 Million INR | 6.42% |
| 2008 | 605.21 Million INR | -8.59% |
| 2007 | 662.11 Million INR | 6.17% |
| 2006 | 623.62 Million INR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2024 Q2 | 4.7 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 4.85 Billion INR | -5.89% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 4.85 Billion INR | 0.0% |
| 2023 Q2 | 5.15 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 5.16 Billion INR | -1.84% |
| 2022 Q4 | 5.16 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 5.81 Billion INR | 0.0% |
| 2021 Q2 | 4.38 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 5.25 Billion INR | 26.73% |
| 2021 Q4 | 5.25 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 4.15 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 3.57 Billion INR | 0.0% |
| 2020 FY | 4.15 Billion INR | 27.53% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 3.25 Billion INR | 31.95% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 2.82 Billion INR | 0.0% |
| 2019 Q4 | 3.25 Billion INR | 0.0% |
| 2018 Q2 | 3.09 Billion INR | 0.0% |
| 2018 Q4 | 2.46 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 FY | 2.46 Billion INR | -11.36% |
| 2018 Q1 | - INR | -100.0% |
| 2017 FY | 2.78 Billion INR | 32.71% |
| 2017 Q4 | 2.78 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 2.37 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 FY | 2.09 Billion INR | 17.54% |
| 2016 Q4 | 2.09 Billion INR | 0.0% |
| 2016 Q2 | 1.98 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 FY | 1.78 Billion INR | 8.62% |
| 2015 Q2 | 2.55 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q4 | 1.78 Billion INR | 0.0% |
| 2014 Q4 | 1.64 Billion INR | 0.0% |
| 2014 FY | 1.64 Billion INR | 29.57% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 1.68 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2013 Q2 | 1.67 Billion INR | 0.0% |
| 2013 Q4 | 1.26 Billion INR | 0.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 FY | 1.26 Billion INR | -10.07% |
| 2012 FY | 1.4 Billion INR | 43.93% |
| 2012 Q4 | 1.4 Billion INR | 0.0% |
| 2012 Q2 | 2.41 Billion INR | 0.0% |
| 2011 FY | 979.07 Million INR | 6.61% |
| 2010 FY | 918.33 Million INR | 42.58% |
| 2009 FY | 644.09 Million INR | 6.42% |
| 2008 FY | 605.21 Million INR | -8.59% |
| 2007 FY | 662.11 Million INR | 6.17% |
| 2006 FY | 623.62 Million INR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Aarey Drugs & Pharmaceuticals Limited | 346.75 Million INR | -1301.239% |
| Aarti Pharmalabs Limited | 6.42 Billion INR | 24.417% |
| Ajanta Pharma Limited | 8.28 Billion INR | 41.343% |
| Alembic Limited | 113.4 Million INR | -4184.744% |
| Alkem Laboratories Limited | 26.61 Billion INR | 81.742% |
| Alembic Pharmaceuticals Limited | 16.43 Billion INR | 70.436% |
| AstraZeneca Pharma India Limited | 2.27 Billion INR | -113.22% |
| Bal Pharma Limited | 878.11 Million INR | -453.334% |
| Biofil Chemicals and Pharmaceuticals Limited | 25.49 Million INR | -18956.752% |
| Bliss GVS Pharma Limited | 1.18 Billion INR | -310.216% |
| Brooks Laboratories Limited | 96.1 Million INR | -4955.667% |
| Bafna Pharmaceuticals Limited | 296.41 Million INR | -1539.205% |
| Caplin Point Laboratories Limited | 3.63 Billion INR | -33.839% |
| Divi's Laboratories Limited | 31.84 Billion INR | 84.74% |
| Eris Lifesciences Limited | 1.89 Billion INR | -157.041% |
| Granules India Limited | 13 Billion INR | 62.64% |
| Ind-Swift Limited | 640.91 Million INR | -658.119% |
| Jagsonpal Pharmaceuticals Limited | 149.97 Million INR | -3139.915% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.02 Billion INR | 3.307% |
| Jubilant Pharmova Limited | 12.89 Billion INR | 62.322% |
| Kilitch Drugs (India) Limited | 39.88 Million INR | -12083.801% |
| Medicamen Biotech Limited | 593.75 Million INR | -718.338% |
| Medico Remedies Limited | 163.37 Million INR | -2874.133% |
| Wockhardt Limited | 6.4 Billion INR | 24.08% |
| Orchid Pharma Limited | 2.64 Billion INR | -83.892% |
| RPG Life Sciences Limited | 1.01 Billion INR | -381.079% |
| Shilpa Medicare Limited | 3.44 Billion INR | -40.867% |
| Sigachi Industries Limited | 707.2 Million INR | -587.055% |
| Solara Active Pharma Sciences Limited | 3.59 Billion INR | -35.082% |
| Unichem Laboratories Limited | 7.04 Billion INR | 31.048% |
| Vaishali Pharma Limited | 3.79 Million INR | -127866.816% |
| Wanbury Limited | 360.23 Million INR | -1248.825% |
| Zydus Lifesciences Limited | 34.41 Billion INR | 85.883% |
| FDC Limited | 3.88 Billion INR | -24.943% |
| Amrutanjan Health Care Limited | 289.04 Million INR | -1581.007% |
| Bajaj HealthCare Limited | 1.44 Billion INR | -237.334% |
| Dr. Reddy's Laboratories Limited | 63.55 Billion INR | 92.354% |
| Glenmark Life Sciences Limited | 6.66 Billion INR | 27.108% |
| Ind-Swift Laboratories Limited | 104.57 Million INR | -4546.242% |
| Laurus Labs Limited | 18.45 Billion INR | 73.67% |
| Mangalam Drugs & Organics Limited | 1.23 Billion INR | -292.988% |
| Nectar Lifesciences Limited | 7.09 Billion INR | 31.483% |
| Par Drugs and Chemicals Limited | 41.77 Million INR | -11532.511% |
| Hester Biosciences Limited | 755.81 Million INR | -542.873% |
| Ipca Laboratories Limited | 24.71 Billion INR | 80.339% |
| Venus Remedies Limited | 1.21 Billion INR | -299.285% |
| ZIM Laboratories Limited | 812.62 Million INR | -497.924% |
| Aurobindo Pharma Limited | 98.08 Billion INR | 95.046% |
| Morepen Laboratories Limited | 2.48 Billion INR | -95.455% |
| Neuland Laboratories Limited | 3.5 Billion INR | -38.659% |
| Sequent Scientific Limited | 3.46 Billion INR | -40.337% |
| Suven Pharmaceuticals Limited | 2.31 Billion INR | -110.164% |
| Valiant Laboratories Limited | 100.15 Million INR | -4751.429% |
| Windlas Biotech Limited | 621.89 Million INR | -681.312% |
| Hikal Limited | 3.03 Billion INR | -59.98% |
| Innova Captab Limited | 1.44 Billion INR | -237.386% |
| Procter & Gamble Health Limited | 1.09 Billion INR | -345.321% |
| Themis Medicare Limited | 705.74 Million INR | -588.48% |
| IOL Chemicals and Pharmaceuticals Limited | 4.24 Billion INR | -14.37% |
| Mankind Pharma Limited | 15.53 Billion INR | 68.722% |
| Glenmark Pharmaceuticals Limited | 25.13 Billion INR | 80.665% |
| Sakar Healthcare Limited | 277.32 Million INR | -1652.072% |
| Albert David Limited | 436.12 Million INR | -1014.117% |
| Lupin Limited | 49.53 Billion INR | 90.192% |
| Gufic Biosciences Limited | 2 Billion INR | -142.361% |
| Sun Pharmaceutical Industries Limited | 98.68 Billion INR | 95.076% |
| Lincoln Pharmaceuticals Limited | 771.68 Million INR | -529.651% |
| Syncom Formulations (India) Limited | 210.81 Million INR | -2204.817% |
| Piramal Enterprises Limited | - INR | -Infinity% |
| Torrent Pharmaceuticals Limited | 22.79 Billion INR | 78.68% |
| NATCO Pharma Limited | 7 Billion INR | 30.637% |
| Suven Life Sciences Limited | 7.08 Million INR | -68480.099% |
| Krebs Biochemicals & Industries Limited | 97.96 Million INR | -4859.883% |
| Strides Pharma Science Limited | 11.26 Billion INR | 56.857% |
| Indoco Remedies Limited | 3.53 Billion INR | -37.623% |
| Alpa Laboratories Limited | 136.65 Million INR | -3455.648% |
| Lasa Supergenerics Limited | 190.43 Million INR | -2451.488% |
| Sun Pharma Advanced Research Company Limited | 14.79 Million INR | -32748.161% |